Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Ipca Laboratories Ltd. Share Price
Day's Range
Low
₹1,813.20
High
₹1,907.10
Price Summary
| Previous Close | ₹1,832.60 |
|---|---|
| Day's Range | ₹1,813.20 - ₹1,907.10 |
| Open | ₹1,907.10 |
| 52 Week Range | ₹1,251.60 - ₹2,038.00 |
| Volume | 2,15,600 |
| Market Cap | ₹0.05 |
| Previous Close | ₹1,836.50 |
|---|---|
| Day's Range | ₹1,812.60 - ₹1,913.95 |
| Open | ₹1,913.95 |
| 52 Week Range | ₹1,252.95 - ₹2,039.30 |
| Volume | 11,996 |
| Market Cap | ₹0.05 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 3,978.30 |
|---|---|
| Market Cap (₹ in Mn) | 0.05 |
| Dividend Yield(%) | 0.33 |
| Price/Earning (TTM) | 35.57 |
| TTM EPS (₹) | 51.63 |
| P/E Ratio | 35.64 |
| Book Value(₹) | 5.49 |
| PAT Margin (%) | 12.35 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 19.41 |
| Trade Value ( ₹ in Lacs) | 221.28 |
|---|---|
| Market Cap (₹ in Mn) | 0.05 |
| Dividend Yield(%) | 0.33 |
| Price/Earning (TTM) | 35.57 |
| TTM EPS (₹) | 51.63 |
| P/E Ratio | 35.64 |
| Book Value(₹) | 5.49 |
| PAT Margin (%) | 12.35 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 19.41 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 17469.0 | 66779.2 |
| Expenses | N/A | N/A |
| PBT | 3567.5 | 9997.7 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 2620.4 | 6507.6 |
About Ipca Laboratories Ltd.
| Founded | 1949 |
|---|---|
| Managing Director | Pranay Godha |
| NSE Symbol | IPCALAB |
Latest News
Ipca Laboratories informs about analyst meet outcome
Ipca Laboratories informs about board meeting
Pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that a meeting of the Board of Directors of the Company will be held on Thursday, 13th August, 2026, to consider and take on record the standalone and consolidated unaudited financial results of the Company for the 1st quarter ended 30th June, 2026 of the financial year 2026-27. Further, with reference to the above meeting of the Board of Directors, it has already informed vide its letter dated 22nd June, 2026 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from 1st July, 2026 and until 48 hours after the declaration of the Company’s unaudited financial results for the 1st quarter ended 30th June, 2026 i.e., till 15th August, 2026.
The above information is a part of company’s filings submitted to BSE.
Acutaas Chemicals informs about updates on acquisition
Shalby informs about company updates
Trident Lifeline informs about newspaper publication
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Ipca Laboratories Ltd. is ₹1,832.60 as of 2026-10-16.
The market capitalisation of Ipca Laboratories Ltd. is ₹46,592.78 as of 2026-10-16.
The 1-year return of Ipca Laboratories Ltd. is 546.30% as of 2026-10-16.
The P/E ratio of Ipca Laboratories Ltd. is 35.64 as of 2026-10-18.
The 52-week high and low of Ipca Laboratories Ltd. are ₹2,038.00 and ₹1,251.60, respectively, as of 2026-10-16.
People Also Ask
Ipca Laboratories Ltd. manufactures a vast array of active pharmaceutical ingredients (APIs) and finished drug formulations. The company holds dominant global market shares in producing anti-malarial, rheumatology, and cardiovascular medications, serving both domestic retail and heavy international export markets.
Ipca Laboratories Ltd. works with global entities by exporting heavily vertically integrated APIs and formulations to over 100 countries. It partners with domestic hospitals and clinics through a massive medical representative network that ensures widespread availability of its specialised generic drugs.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
